The DOI matches its Crossref record; 28 of the 28 references it cites were found in a registry or an index.
Targeting CXCL12 from FAP-expressing carcinoma-associated fibroblasts synergizes with anti-PD-L1 immunotherapy in pancreatic cancer
Open accessAbstract
Significance: Cancer immune evasion is well described. In some cases, this may be overcome by enhancing T-cell responses. We show that despite the presence of antitumor T cells, immunotherapeutic antibodies are ineffective in a murine pancreatic cancer model recapitulating the human disease. Removing the carcinoma-associated fibroblast (CAF) expressing fibroblast activation protein (FAP) from tumors permitted immune control of tumor growth and uncovered the efficacy of these immunotherapeutic antibodies. FAP + CAFs are the only tumoral source of chemokine (C-X-C motif) ligand 12 (CXCL12), and administering AMD3100, an inhibitor of chemokine (C-X-C motif) receptor 4, a CXCL12 receptor, also revealed the antitumor effects of an immunotherapeutic antibody and greatly diminished cancer cells. These findings may have wide clinical relevance because FAP + cells are found in almost all human adenocarcinomas.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“targeting CXCL12 signalling could be considered to be targeting CAFs as they are the major source of the chemokine in many tumours121.”
From A framework for advancing our understanding of cancer-associated fibroblasts (2020) · cites this paper as [121]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“most studies have suggested an immunosuppressive role of CAFs121”
From A framework for advancing our understanding of cancer-associated fibroblasts (2020) · cites this paper as [121]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Interference with the action of CXCL12 produced by CAFs promotes T cell-mediated tumour control16,121,122”
From A framework for advancing our understanding of cancer-associated fibroblasts (2020) · cites this paper as [121]
In the citing paper
“the transcriptional profiles of apCAFs overlap with mesothelial cells150, and based on lineage tracing studies in mice have been postulated to derive from a mesothelial origin145”
From Pancreatic cancer: Advances and challenges (2023) · cites this paper as [150]
In the citing paper
“They can further differentiate into myofibroblasts that express α-smooth muscle actin232.”
From TGFβ biology in cancer progression and immunotherapy (2021) · cites this paper as [232]
In the citing paper
“fibroblast activation protein (FAP)+ CAFs inhibited anti-tumor function of T cells in gastric cancer and pancreatic cancer and targeting these FAP+ subtypes enhanced tumor response to ICB (Feig et al., 2013).”
From Hallmarks of response, resistance, and toxicity to immune checkpoint blockade (2021) · cites this paper as Feig et al., 2013
In the citing paper
“Moreover, CAF depletion using diphtheria toxin‐based immunotherapy reduced cancer growth by increasing CD8+ Teff‐cell infiltration to the TME [102].”
From Tumor microenvironment signaling and therapeutics in cancer progression (2023) · cites this paper as [102]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
Hartkopf, A. D., Taran, F., Wallwiener, M., Walter, C. B., Krämer, B., Grischke, E., & Brucker, S. Y. (2016) · Breast Care · doi:10.1159/000453569 · Cited by 30,989
Adverse Renal Effects of Immune Checkpoint Inhibitors: A Narrative Review
Wanchoo, R., Karam, S., Uppal, N. N., Barta, V. S., Deray, G., Devoe, C., Launay‐Vacher, V., Jhaveri, K. D., & on behalf of Cancer and Kidney International Network Workgroup on Immune Checkpoint Inhibitors (2017) · American Journal of Nephrology · doi:10.1159/000455014 · Cited by 15,320
Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
Hodi, F. S., O'Day, S. J., McDermott, D. F., Weber, R. W., Sosman, J. A., Haanen, J. B., Gonzalez, R., Robert, C., Schadendorf, D., Hassel, J. C., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1003466 · Cited by 15,155
Safety and activity of anti-PD-L1 antibody in patients with advanced cancer
Brahmer, J. R., Tykodi, S. S., Chow, L. Q. M., Hwu, W.-J., Topalian, S. L., Hwu, P., Drake, C. G., Camacho, L. H., Kauh, J., Odunsi, K., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1200694 · Cited by 7,945
Tumor-associated B7-H1 promotes T-cell apoptosis: A potential mechanism of immune evasion
Dong, H., Strome, S. E., Salomao, D. R., Tamura, H., Hirano, F., Flies, D. B., Roche, P. C., Lu, J., Zhu, G., Tamada, K., et al. (2002) · Nature Medicine · doi:10.1038/nm730 · Cited by 5,025
Nivolumab plus Ipilimumab in Advanced Melanoma
Wolchok, J. D., Kluger, H., Callahan, M. K., Postow, M. A., Rizvi, N. A., Lesokhin, A. M., Segal, N. H., Ariyan, C. E., Gordon, R.-A., Reed, K., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1302369 · Cited by 4,230
Enhancement of Antitumor Immunity by CTLA-4 Blockade
Leach, D. R., Krummel, M. F., & Allison, J. P. (1996) · Science · doi:10.1126/science.271.5256.1734 · Cited by 3,955
Orimo, A., Gupta, P. B., Sgroi, D. C., Arenzana-Seisdedos, F., Delaunay, T., Naeem, R., Carey, V. J., Richardson, A. L., & Weinberg, R. A. (2005) · Cell · doi:10.1016/j.cell.2005.02.034 · Cited by 3,759
Safety and Tumor Responses with Lambrolizumab (Anti–PD-1) in Melanoma
Hamid, O., Robert, C., DAUD, A. I., Hodi, F. S., Hwu, W., Kefford, R. F., Wolchok, J. D., Hersey, P., Joseph, R. W., Weber, J. S., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1305133 · Cited by 3,427
Intratumoral T Cells, Recurrence, and Survival in Epithelial Ovarian Cancer
Zhang, L., Conejo-Garcia, J. R., Katsaros, D., Gimotty, P. A., Massobrio, M., Regnani, G., Makrigiannakis, A., Gray, H., Schlienger, K., Liebman, M. N., et al. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa020177 · Cited by 3,397
Cited by
Sorted by citations
Items 201–300 of 1,000
Tumor-associated fibrosis as a regulator of tumor immunity and response to immunotherapy
Jiang, H., Hegde, S., & DeNardo, D. G. (2017) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-017-2003-1 · Cited by 246
The CXCL12-CXCR4/CXCR7 axis as a mechanism of immune resistance in gastrointestinal malignancies
Daniel, S. K., Seo, Y. D., & Pillarisetty, V. G. (2019) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2019.12.007 · Cited by 241
Cancer associated fibroblasts in cancer development and therapy
Jia, H., Chen, X., Zhang, L., & Chen, M. (2025) · Journal of Hematology & Oncology · doi:10.1186/s13045-025-01688-0 · Cited by 262
Heterogeneity in Cancer Metabolism: New Concepts in an Old Field
Gentric, G., Mieulet, V., & Mechta‐Grigoriou, F. (2016) · Antioxidants and Redox Signaling · doi:10.1089/ars.2016.6750 · Cited by 248
Enhancing CAR-T cell efficacy in solid tumors by targeting the tumor microenvironment
Liu, G., Rui, W., Zhao, X., & Lin, X. (2021) · Cellular and Molecular Immunology · doi:10.1038/s41423-021-00655-2 · Cited by 244
Helms, E. J., Berry, M. W., Chaw, R. C., DuFort, C. C., Sun, D., Onate, M. K., Oon, C., Bhattacharyya, S., Sanford-Crane, H., Horton, W., et al. (2022) · Cancer Discovery · doi:10.1158/2159-8290.cd-21-0601 · Cited by 238
Current and future immunotherapeutic approaches in pancreatic cancer treatment
Farhangnia, P., Khorramdelazad, H., Nickho, H., & Delbandi, A. (2024) · Journal of Hematology & Oncology · doi:10.1186/s13045-024-01561-6 · Cited by 265
Candido, J. B., Morton, J. P., Bailey, P., Campbell, A. D., Karim, S. A., Jamieson, T., Lapienyte, L., Gopinathan, A., Clark, W., McGhee, E. J., et al. (2018) · Cell Reports · doi:10.1016/j.celrep.2018.03.131 · Cited by 224
Self-citationTargeting Pin1 renders pancreatic cancer eradicable by synergizing with immunochemotherapy
Koikawa, K., Kibe, S., Suizu, F., Sekino, N., Kim, N., Manz, T. D., Pinch, B. J., Akshinthala, D., Verma, A., Gaglia, G., et al. (2021) · Cell · doi:10.1016/j.cell.2021.07.020 · Cited by 243
Recent advances in active targeting of nanomaterials for anticancer drug delivery
Dutta, B., Barick, K. C., & Hassan, P. A. (2021) · Advances in Colloid and Interface Science · doi:10.1016/j.cis.2021.102509 · Cited by 236
Yang, L., He, Y.-T., Dong, S., Wei, X., Chen, Z., Zhang, B., Chen, W., Yang, X., Wang, F., Shang, X.-M., et al. (2022) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2021-003534 · Cited by 234
Wang, F., Long, J., Li, L., Wu, Z., Da, T.-T., Wang, X., Huang, C., Jiang, Y., Yao, X., Ma, H., et al. (2023) · Science Advances · doi:10.1126/sciadv.adf5464 · Cited by 263
Current advances and outlooks in immunotherapy for pancreatic ductal adenocarcinoma
Fan, J., Wang, M., Chen, H., Shang, D., Das, J. K., & Song, J. J. (2020) · Molecular Cancer · doi:10.1186/s12943-020-01151-3 · Cited by 230
Seo, Y. D., Jiang, X., Sullivan, K. M., Jalikis, F. G., Smythe, K. S., Abbasi, A., Vignali, M., Park, J. O., Daniel, S. K., Pollack, S. M., et al. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-0081 · Cited by 227
The evolving relationship of wound healing and tumor stroma
Foster, D. S., Jones, R. E., Ransom, R. C., Longaker, M. T., & Norton, J. A. (2018) · JCI Insight · doi:10.1172/jci.insight.99911 · Cited by 227
Two-Step Senescence-Focused Cancer Therapies
Sieben, C. J., Sturmlechner, I., van de Sluis, B., & van Deursen, J. M. (2018) · Trends in Cell Biology · doi:10.1016/j.tcb.2018.04.006 · Cited by 222
CAR T‐cell therapy of solid tumors
Yong, C. S. M., Dardalhon, V., Devaud, C., Taylor, N. N., Darcy, P. K., & Kershaw, M. H. (2016) · Immunology and Cell Biology · doi:10.1038/icb.2016.128 · Cited by 226
Cancer-associated fibroblasts in pancreatic ductal adenocarcinoma
Zhang, T., Ren, Y., Yang, P., Wang, J., & Zhou, H. (2022) · Cell Death and Disease · doi:10.1038/s41419-022-05351-1 · Cited by 240
PD‐L1 blockade enhances response of pancreatic ductal adenocarcinoma to radiotherapy
Azad, A. K., Lim, S. Y., D’Costa, Z., Jones, K. I., Diana, A., Sansom, O. J., Krüger, P., Liu, S. K., McKenna, W. G., Dushek, O., et al. (2016) · EMBO Molecular Medicine · doi:10.15252/emmm.201606674 · Cited by 217
Aptamer Therapeutics in Cancer: Current and Future
Morita, Y., Leslie, M., Kameyama, H., Volk, D. E., & Tanaka, T. (2018) · Cancers · doi:10.3390/cancers10030080 · Cited by 219
Cancer‐associated fibroblasts: Key players in shaping the tumor immune microenvironment
Desbois, M., & Wang, Y. (2021) · Immunological Reviews · doi:10.1111/imr.12982 · Cited by 221
Innate Immunity and Cancer Pathophysiology
Maiorino, L., Daßler‐Plenker, J., Sun, L., & Egeblad, M. (2021) · Annual Review of Pathology Mechanisms of Disease · doi:10.1146/annurev-pathmechdis-032221-115501 · Cited by 233
Zhang, A., Qian, Y., Zhou, Y., Chen, H., Xie, H., Zhou, L., Shen, Y., & Zheng, S. (2017) · Cancer Medicine · doi:10.1002/cam4.993 · Cited by 219
EGFR-activated myofibroblasts promote metastasis of pancreatic cancer
Mucciolo, G., Henríquez, J. A., Jihad, M., Teles, S. P., Manansala, J. S., Li, W., Ashworth, S., Lloyd, E. G., Cheng, P. S. W., Luo, W., et al. (2023) · Cancer Cell · doi:10.1016/j.ccell.2023.12.002 · Cited by 224
Targeting of activated fibroblasts for imaging and therapy
Lindner, T., Loktev, A., Giesel, F., Kratochwil, C., Altmann, A., & Haberkorn, U. (2019) · EJNMMI Radiopharmacy and Chemistry · doi:10.1186/s41181-019-0069-0 · Cited by 205
Modeling Pancreatic Cancer with Organoids
Baker, L. A., Tiriac, H., Clevers, H. C., & Tuveson, D. A. (2016) · Trends in cancer · doi:10.1016/j.trecan.2016.03.004 · Cited by 227
Self-citationThe Role of CXC Chemokine Receptors 1–4 on Immune Cells in the Tumor Microenvironment
Susek, K. H., Karvouni, M., Alici, E., & Lundqvist, A. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.02159 · Cited by 212
Grauel, A. L., Nguyen, B., Ruddy, D., Laszewski, T., Schwartz, S., Chang, J., Chen, J., Piquet, M., Pelletier, M., Yan, Z., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-19920-5 · Cited by 211
Fibroblast activation protein-based theranostics in cancer research: A state-of-the-art review
Zhao, L., Chen, J., Pang, Y., Fu, K., Shang, Q., Wu, H., Sun, L., Lin, Q., & Chen, H. (2022) · Theranostics · doi:10.7150/thno.69475 · Cited by 209
Lee, J. W., Komar, C. A., Bengsch, F., Graham, K. L., & Beatty, G. L. (2016) · Current Protocols in Pharmacology · doi:10.1002/cpph.2 · Cited by 212
Hypoxia as a barrier to immunotherapy in pancreatic adenocarcinoma
Daniel, S. K., Sullivan, K. M., Labadie, K. P., & Pillarisetty, V. G. (2019) · Clinical and Translational Medicine · doi:10.1186/s40169-019-0226-9 · Cited by 215
Regulation and modulation of antitumor immunity in pancreatic cancer
Leinwand, J., & Miller, G. (2020) · Nature Immunology · doi:10.1038/s41590-020-0761-y · Cited by 207
Cremasco, V., Astarita, J. L., Grauel, A. L., Keerthivasan, S., MacIsaac, K. D., Woodruff, M. C., Wu, M. P., Spel, L., Santoro, S. P., Amoozgar, Z., et al. (2018) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-18-0098 · Cited by 210
Chauhan, V. P., Chen, I. X., Tong, R., Ng, M. R., Martin, J. D., Naxerova, K., Wu, M. W., Huang, P., Boucher, Y., Kohane, D. S., et al. (2019) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1819889116 · Cited by 205
Context-Specific Determinants of the Immunosuppressive Tumor Microenvironment in Pancreatic Cancer
Falcomatà, C., Bärthel, S., Schneider, G., Rad, R., Schmidt‐Supprian, M., & Saur, D. (2023) · Cancer Discovery · doi:10.1158/2159-8290.cd-22-0876 · Cited by 224
Xin, L., Gao, J., Zheng, Z., Chen, Y., Lv, S., Zhao, Z., Yu, C., Yang, X., & Zhang, R. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.648187 · Cited by 203
Obradovic, A., Graves, D. K., Korrer, M. J., Wang, Y., Roy, S., Naveed, A., Xu, Y., Luginbuhl, A., Curry, J., Gibson, M. K., et al. (2022) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-21-3570 · Cited by 215
Bulle, A. S., & Lim, K. (2020) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-020-00341-1 · Cited by 208
CAFs Interacting With TAMs in Tumor Microenvironment to Enhance Tumorigenesis and Immune Evasion
Günaydın, G. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.668349 · Cited by 211
Heßmann, E., Patzak, M. S., Klein, L., Chen, N., Kari, V., Ramu, I., Bapiro, T. E., Frese, K. K., Gopinathan, A., Richards, F. M., et al. (2017) · Gut · doi:10.1136/gutjnl-2016-311954 · Cited by 205
Self-citationReshaping the Tumor Stroma for Treatment of Pancreatic Cancer
Vennin, C., Murphy, K. J., Morton, J. P., Cox, T. R., Pajic, M., & Timpson, P. (2017) · Gastroenterology · doi:10.1053/j.gastro.2017.11.280 · Cited by 207
The tumour microenvironment and immune milieu of cholangiocarcinoma
Fabris, L., Perugorria, M. J., Mertens, J., Björkström, N. K., Cramer, T., Lleo, A., Solinas, A., Sänger, H., Lukacs‐Kornek, V., Moncsek, A., et al. (2019) · Liver International · doi:10.1111/liv.14098 · Cited by 187
Stromnes, I. M., Schmitt, T. M., Hulbert, A., Brockenbrough, J. S., Nguyen, H., Cuevas, C. M., Dotson, A., Tan, X., Hotes, J. L., Greenberg, P. D., et al. (2015) · Cancer Cell · doi:10.1016/j.ccell.2015.09.022 · Cited by 201
Cancer-associated fibroblasts promote the progression of endometrial cancer via the SDF-1/CXCR4 axis
Teng, F., Tian, W., Wang, Y., Zhang, Y., Guo, F., Zhao, J., Gao, C., & Xue, F. (2016) · Journal of Hematology & Oncology · doi:10.1186/s13045-015-0231-4 · Cited by 206
T-cell Localization, Activation, and Clonal Expansion in Human Pancreatic Ductal Adenocarcinoma
Stromnes, I. M., Hulbert, A., Pierce, R. H., Greenberg, P. D., & Hingorani, S. R. (2017) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-16-0322 · Cited by 206
Targeting the Myofibroblastic Cancer-Associated Fibroblast Phenotype Through Inhibition of NOX4
Hanley, C. J., Mellone, M., Ford, K., Thirdborough, S. M., Mellows, T., Frampton, S. J., Smith, D. M., Harden, E., Szyndralewiez, C., Bullock, M., et al. (2018) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/djx121 · Cited by 195
CAFs and TAMs: maestros of the tumour microenvironment
Komohara, Y., & Takeya, M. (2016) · The Journal of Pathology · doi:10.1002/path.4824 · Cited by 199
Hu, S., Ma, J., Su, C., Chen, Y., Shu, Y., Qi, Z., Zhang, B., Shi, G., Zhang, Y., Zhang, Y., et al. (2021) · Acta Biomaterialia · doi:10.1016/j.actbio.2021.09.003 · Cited by 196
Study and analysis of antitumor resistance mechanism of PD1/PD‐L1 immune checkpoint blocker
Wang, Z., & Wu, X. (2020) · Cancer Medicine · doi:10.1002/cam4.3410 · Cited by 205
Extracellular Matrices and Cancer-Associated Fibroblasts: Targets for Cancer Diagnosis and Therapy?
Belhabib, I., Zaghdoudi, S., Lac, C., Bousquet, C., & Jean, C. (2021) · Cancers · doi:10.3390/cancers13143466 · Cited by 210
New perspectives in cancer immunotherapy: targeting IL-6 cytokine family
Soler, M. F., Abaurrea, A., Azcoaga, P., Araujo, A. M., & Caffarel, M. M. (2023) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2023-007530 · Cited by 208
The impact of cancer-associated fibroblasts on major hallmarks of pancreatic cancer
Sun, Q., Zhang, B., Hu, Q., Qin, Y., Xu, W., Liu, W., Yu, X., & Xu, J. (2018) · Theranostics · doi:10.7150/thno.26546 · Cited by 201
Gorchs, L., Moro, C. F., Bankhead, P., Kern, K. P., Sadeak, I., Meng, Q., Rangelova, E. B., & Kaipe, H. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.00847 · Cited by 197
Panagi, M., Voutouri, C., Mpekris, F., Papageorgis, P., Martin, M. R., Martin, J. D., Demetriou, P., Pierides, C., Polydorou, C., Stylianou, A., et al. (2020) · Theranostics · doi:10.7150/thno.36936 · Cited by 195
Zeng, Y. C., Li, B., Liang, Y., Reeves, P. M., Qu, X., Ran, C., Liu, Q., Callahan, M. V., Sluder, A. E., Gelfand, J. A., et al. (2019) · The FASEB Journal · doi:10.1096/fj.201802067rr · Cited by 192
Cancer‐associated fibroblasts promote PD‐L1 expression in mice cancer cells via secreting CXCL5
Li, Z., Zhou, J., Zhang, J., Li, S., Wang, H., & Du, J. (2019) · International Journal of Cancer · doi:10.1002/ijc.32278 · Cited by 192
Knudsen, E. S., Vail, P. J., Balaji, U., Ngo, H., Botros, I. W., Makarov, V., Riaz, N., Balachandran, V. P., Leach, S. D., Thompson, D. M., et al. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-0162 · Cited by 190
The Pancreatic Cancer Microenvironment
Dougan, S. K. (2017) · The Cancer Journal · doi:10.1097/ppo.0000000000000288 · Cited by 193
Chemokine-Directed Tumor Microenvironment Modulation in Cancer Immunotherapy
Bule, P., Aguiar, S. I., Aires‐da‐Silva, F., & Dias, J. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22189804 · Cited by 196
Cancer-Associated Fibroblast (CAF) Heterogeneity and Targeting Therapy of CAFs in Pancreatic Cancer
Geng, X., Chen, H., Zhao, L., Hu, J., Yang, W., Li, G., Cheng, C., Zhao, Z., Zhang, T., Li, L., et al. (2021) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2021.655152 · Cited by 202
Nguyen, M., De Ninno, A., Mencattini, A., Mermet-Meillon, F., Fornabaio, G., Evans, S. S., Cossutta, M., Khira, Y., Han, W., Sirven, P., et al. (2018) · Cell Reports · doi:10.1016/j.celrep.2018.12.015 · Cited by 184
MYC Instructs and Maintains Pancreatic Adenocarcinoma Phenotype
Sodir, N. M., Kortlever, R. M., Barthet, V. J. A., Campos, T., Pellegrinet, L., Kupczak, S., Anastasiou, P., Swigart, L. B., Soucek, L., Arends, M. J., et al. (2020) · Cancer Discovery · doi:10.1158/2159-8290.cd-19-0435 · Cited by 188
Munir, H., Jones, J. O., Janowitz, T., Hoffmann, M. H., Euler, M., Martins, C. P., Welsh, S. J., & Shields, J. D. (2021) · Nature Communications · doi:10.1038/s41467-021-20982-2 · Cited by 186
Self-citationCharacterizing dedifferentiation of thyroid cancer by integrated analysis
Luo, H., Xia, X., Kim, G. D., Liu, Y., Xue, Z., Zhang, L., Shu, Y., Yang, T., Chen, Y., Zhang, S., et al. (2021) · Science Advances · doi:10.1126/sciadv.abf3657 · Cited by 181
Lack of immunoediting in murine pancreatic cancer reversed with neoantigen
Evans, R. A., Diamond, M. S., Rech, A. J., Chao, T., Richardson, M. W., Lin, J., Bajor, D. L., Byrne, K. T., Stanger, B. Z., Riley, J. L., et al. (2016) · JCI Insight · doi:10.1172/jci.insight.88328 · Cited by 181
CXCL12/CXCR4 axis in the microenvironment of solid tumors: A critical mediator of metastasis
Mortezaee, K. (2020) · Life Sciences · doi:10.1016/j.lfs.2020.117534 · Cited by 180
Kabacaoğlu, D., Ciecielski, K. J., Ruess, D. A., & Algül, H. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.01878 · Cited by 181
Cancer‐associated fibroblasts that restrain cancer progression: Hypotheses and perspectives
Miyai, Y., Esaki, N., Takahashi, M., & Enomoto, A. (2020) · Cancer Science · doi:10.1111/cas.14346 · Cited by 180
Wei, L., Ye, H., Li, G., Lu, Y., Zhou, Q., Zheng, S., Lin, Q., Liu, Y., Li, Z., & Chen, R. (2018) · Cell Death and Disease · doi:10.1038/s41419-018-1104-x · Cited by 179
Nanoformulations for combination or cascade anticancer therapy
Miao, L., Guo, S., Lin, C. M., Liu, Q., & Huang, L. (2017) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2017.06.003 · Cited by 178
Djurec, M., Graña‐Castro, O., Lee, A., Troulé, K., Espinet, E., Cabras, L., Navas, C., Blasco, M. T., Martín-Díaz, L., Burdiel, M., et al. (2018) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1717802115 · Cited by 178
Type 1 conventional dendritic cells are systemically dysregulated early in pancreatic carcinogenesis
Lin, J. H., Huffman, A. P., Wattenberg, M. M., Walter, D. M., Carpenter, E. L., Feldser, D. M., Beatty, G. L., Furth, E. E., & Vonderheide, R. H. (2020) · The Journal of Experimental Medicine · doi:10.1084/jem.20190673 · Cited by 175
Lin, Y., Cai, Q., Chen, Y., Shi, T., Liu, W., Li, M., Deng, B., Ying, Z., Gao, Y., Luo, H., et al. (2021) · Hepatology · doi:10.1002/hep.32099 · Cited by 181
Pancreatic cancer: Stroma and its current and emerging targeted therapies
Kota, J., Hancock, J., Kwon, J. J., & Korc, M. (2017) · Cancer Letters · doi:10.1016/j.canlet.2016.12.035 · Cited by 177
Understanding and overcoming the resistance of cancer to PD-1/PD-L1 blockade
Shergold, A. L., Millar, R., & Nibbs, R. J. B. (2019) · Pharmacological Research · doi:10.1016/j.phrs.2019.104258 · Cited by 176
Bhagat, T. D., Ahrens, D. V., Dawlaty, M. M., Zou, Y., Baddour, J., Achreja, A., Zhao, H., Yang, L., Patel, B., Kwak, C., et al. (2019) · eLife · doi:10.7554/elife.50663 · Cited by 178
Emerging roles of the CXCL12/CXCR4 axis in pancreatic cancer progression and therapy
Sleightholm, R. L., Neilsen, B. K., Li, J., Steele, M. M., Singh, R. K., Hollingsworth, M. A., & Oupický, D. (2017) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2017.05.012 · Cited by 171
Freedman, J. D., Duffy, M. R., Lei-Rossmann, J., Muntzer, A., Scott, E. M., Hagel, J., Campo, L., Bryant, R. J., Verrill, C. L., Lambert, A. G., et al. (2018) · Cancer Research · doi:10.1158/0008-5472.can-18-1750 · Cited by 176
Overcoming Challenges for CD3-Bispecific Antibody Therapy in Solid Tumors
Middelburg, J., Kemper, K., Engelberts, P. J., Labrijn, A. F., Schuurman, J., & van Hall, T. (2021) · Cancers · doi:10.3390/cancers13020287 · Cited by 178
Li, X., Bu, W.-H., Meng, L., Liu, X.-C., Wang, S.-S., Jiang, L., Ren, M.-S., Fan, Y., & Sun, H.-C. (2019) · Experimental Cell Research · doi:10.1016/j.yexcr.2019.03.013 · Cited by 163
Exploiting the neoantigen landscape for immunotherapy of pancreatic ductal adenocarcinoma
Bailey, P. J., Chang, D. K.-F., Forget, M., Lucas, F. A. S., Alvarez, H. A., Haymaker, C., Chattopadhyay, C., Kim, S.-H., Ekmekçioglu, S., Grimm, E. A., et al. (2016) · Scientific Reports · doi:10.1038/srep35848 · Cited by 172
Deciphering the spatial landscape and plasticity of immunosuppressive fibroblasts in breast cancer
Croizer, H., Mhaidly, R., Kieffer, Y., Gentric, G., Djerroudi, L., Leclère, R., Pelon, F., Robley, C., Bohec, M., Meng, A., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-47068-z · Cited by 183
Pancreatic Cancer, Inflammation, and Microbiome
Zambirinis, C. P., Pushalkar, S., Saxena, D. B., & Miller, G. (2014) · The Cancer Journal · doi:10.1097/ppo.0000000000000045 · Cited by 171
Chen, S., Morine, Y., Tokuda, K., Yamada, S., Saito, Y., Nishi, M., Ikemoto, T., & Shimada, M. (2021) · International Journal of Oncology · doi:10.3892/ijo.2021.5239 · Cited by 169
Zheng, S., Wang, W., Shen, L., Yao, Y., Xia, W., & Ni, C. (2024) · Experimental Hematology and Oncology · doi:10.1186/s40164-024-00543-1 · Cited by 200
Cancer Stem Cells and Their Microenvironment: Biology and Therapeutic Implications
Lau, E. Y.-T., Ho, N. P. Y., & Lee, T. K. (2017) · Stem Cells International · doi:10.1155/2017/3714190 · Cited by 174
Quaranta, V., Rainer, C., Nielsen, S. R., Raymant, M., Ahmed, M. S., Engle, D. D., Taylor, A., Murray, T., Campbell, F., Palmer, D. H., et al. (2018) · Cancer Research · doi:10.1158/0008-5472.can-17-3876 · Cited by 171
Self-citationZboralski, D., Hoehlig, K., Eulberg, D., Frömming, A., & Vater, A. (2017) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-16-0303 · Cited by 172
Strategies for Increasing Pancreatic Tumor Immunogenicity
Johnson, B. A., Yarchoan, M. M., Lee, V., Laheru, D. A., & Jaffee, E. M. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-2318 · Cited by 166
Fibroblast-derived CXCL12 promotes breast cancer metastasis by facilitating tumor cell intravasation
Ahirwar, D. K., Nasser, M. W., Ouseph, M. M., Elbaz, M., Cuitiño, M. C., Kladney, R. D., Varikuti, S., Kaul, K., Satoskar, A. R., Ramaswamy, B., et al. (2018) · Oncogene · doi:10.1038/s41388-018-0263-7 · Cited by 162
Targeting fibroblast activation protein in cancer ndash Prospects and caveats
Šedo, A. (2018) · Frontiers in bioscience · doi:10.2741/4682 · Cited by 166
Barriers and opportunities in pancreatic cancer immunotherapy
Ju, Y., Xu, D., Liao, M.-M., Sun, Y., Bao, W.-D., Yao, F., & Ma, L. (2024) · npj Precision Oncology · doi:10.1038/s41698-024-00681-z · Cited by 174
Tumour Cell Secretome in Chemoresistance and Tumour Recurrence
Madden, E. C., Gorman, A. M., Logue, S. E., & Samali, A. (2020) · Trends in cancer · doi:10.1016/j.trecan.2020.02.020 · Cited by 161
Lo, A., Li, C., Buza, E. L., Blomberg, R., Govindaraju, P. K., Avery, D., Monslow, J., Hsiao, M., & Puré, E. (2017) · JCI Insight · doi:10.1172/jci.insight.92232 · Cited by 164
Cancer associated fibroblasts: is the force the path to the dark side?
Barbazán, J., & Vignjevic, D. M. (2018) · Current Opinion in Cell Biology · doi:10.1016/j.ceb.2018.09.002 · Cited by 166
Fibroblasts Fuel Immune Escape in the Tumor Microenvironment
Jaeghere, E. A. D., Denys, H. G., & Wever, O. D. (2019) · Trends in cancer · doi:10.1016/j.trecan.2019.09.009 · Cited by 163
Xie, Y., Yu, H., Wang, Y., Sleightholm, R. L., Prajapati, D. R., Bader, J., Yu, A., Tang, W., Jaramillo, L., Li, J., et al. (2020) · ACS Nano · doi:10.1021/acsnano.9b03978 · Cited by 162
Intrinsic Resistance of Solid Tumors to Immune Checkpoint Blockade Therapy
Zhao, X., & Subramanian, S. (2017) · Cancer Research · doi:10.1158/0008-5472.can-16-2379 · Cited by 162
Enhancing Tumor T Cell Infiltration to Enable Cancer Immunotherapy
Zhang, J., Endres, S., & Kobold, S. (2019) · Immunotherapy · doi:10.2217/imt-2018-0111 · Cited by 159
Mechanisms of T-Cell Exhaustion in Pancreatic Cancer
Saka, D., Gökalp, M., Piyade, B., Çevik, N. C., Sever, E. A., Unutmaz, D., Ceyhan, G. O., Demir, İ. E., & Asimgil, H. (2020) · Cancers · doi:10.3390/cancers12082274 · Cited by 160
Metadata
- Authors
- Feig, C., Jones, J. O., Kraman, M., Wells, R. J. B., Deonarine, A., Chan, D. S., Connell, C. M., Roberts, E. W., Zhao, Q., Caballero, O. L., Teichmann, S. A., Janowitz, T., Jodrell, D. I., Tuveson, D. A., & Fearon, D. T.
- Affiliations
- University of Cambridge (GB)
- MRC Laboratory of Molecular Biology (GB)
- Johns Hopkins University (US)
- Ludwig Collaborative Laboratory, Department of Neurosurgery, The Johns Hopkins University School of Medicine, Baltimore, MD 21231; and
- European Bioinformatics Institute (GB)
- ORCID
- Venue
- Proceedings of the National Academy of Sciences
- Publisher
- National Academy of Sciences
- Published
- 2013-11-25
- Volume
- 110
- Issue
- 50
- Pages
- 20212-20217
- ISSN
- 0027-8424 (ISSN-L)
- 1091-6490
- PMC
- PMC3864274
- OpenAlex
- W2086834665
- Cited by
- 2,100
- References
- 28
- Citations by year
- 2026: 252 · 2025: 157 · 2024: 226 · 2023: 214 · 2022: 221 · 2021: 244 · 2020: 203 · 2019: 149 · 2018: 125 · 2017: 119 · 2016: 95 · 2015: 63 · 2014: 30
- FWCI
- 33.71
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Proceedings of the National Academy of Sciences (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Cold Spring Harbor Laboratory Institutional Repository (Cold Spring Harbor Laboratory) (acceptedVersion)
- ENLIGHTEN (Jurnal Bimbingan dan Konseling Islam) (submittedVersion)
- Funders
- Wellcome Trust
- Cancer Research UK (15678)
- National Institute for Health and Care Research (CL-2011-14-007)
- Medical Research Council (MC_PC_12012)
- Topics
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Health Sciences › Medicine › Oncology › Pancreatic and Hepatic Oncology Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Biochemistry › Peptidase Inhibition and Analysis
- Keywords
- pancreatic ductal adenocarcinoma, CXCL12, fibroblast activation protein, cancer-associated fibroblasts, PD-L1 blockade, CTLA-4 blockade, tumor immune evasion, tumor stroma, CXCR4 inhibition, AMD3100, CD8+ T cells, chemokine signaling, immunotherapy resistance
- MeSH terms
- Cyclams, Fibroblast Activation Protein Alpha, Analysis of Variance, Animals, Base Sequence, Benzylamines, Fibroblasts, Flow Cytometry, Fluorescent Antibody Technique, Heterocyclic Compounds, Immunohistochemistry, Immunotherapy, Membrane Proteins, Molecular Sequence Data, Pancreatic Neoplasms, Endopeptidases, Serine Endopeptidases, Sequence Analysis, RNA, Gelatinases, Tumor Escape, Carcinoma, Pancreatic Ductal, Mice, Chemokine CXCL12, Enzyme-Linked Immunospot Assay
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
